One Shot to Silence a Gene Forever. AHA Wants to See the Receipts.
CRISPR Therapeutics just landed a coveted late-breaking slot at AHA 2026 for its one-shot gene-editing heart therapy, CTX310. The Phase 1b data could answer whether permanently silencing a single gene is the future of cardiovascular medicine.
The Biggest Stage in Cardiology Just Called
Imagine you could take a single IV drip, walk out of the clinic, and never worry about your cholesterol again. No daily pills. No monthly injections. One treatment, and a problematic gene goes quiet for good.
That's the pitch behind CRISPR Therapeutics' CTX310, and the American Heart Association just gave it one of the most coveted speaking slots in all of medicine: a late-breaking oral presentation at the 2026 Scientific Sessions on November 9.
Late-breakers at AHA aren't participation trophies. These slots are reserved for data the committee believes could reshape how doctors think about cardiovascular disease. Getting selected means the gatekeepers of cardiology looked at what's coming and said, "The world needs to see this."
So what exactly is CRISPR bringing to the podium?
A Molecular Delete Button for Bad Lipids
CTX310 works like a find-and-replace tool, except it only does the "delete" part. The therapy packages two components (a Cas9 protein's instructions and a guide RNA) inside a lipid nanoparticle, which is essentially a tiny fat bubble that ferries the cargo straight to liver cells.
Once inside a hepatocyte, the Cas9 machinery hunts down a gene called ANGPTL3 and snips it. The cell tries to repair the cut but fumbles, permanently disabling the gene. That matters because ANGPTL3 acts like a brake on the body's lipid-clearing enzymes. Remove the brake, and your body gets much better at mopping up triglycerides and LDL cholesterol on its own.
The beauty of gene editing over traditional drugs: you do it once. Statins work every day you take them. Stop taking them, and your cholesterol climbs right back. CTX310 aims to be a one-and-done treatment that rewrites the instruction manual your liver follows for the rest of your life.
The Phase 1 Data That Earned the Invitation
CRISPR didn't get this AHA slot on vibes alone. The Phase 1 first-in-human study already produced some jaw-dropping numbers.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
At the highest dose tested, patients saw mean reductions of roughly 73% in ANGPTL3 protein, 55% in triglycerides, and 49% in LDL cholesterol. The best individual responses were even more dramatic, with peak reductions hitting 89%, 84%, and 87% for those same markers, respectively.
Perhaps most importantly, those effects stuck around. A one-year follow-up showed the reductions were deep and durable after just a single infusion. No booster shots. No refills.
On safety, the early data looked clean. No treatment-related serious adverse events were reported across the dose cohorts. Liver enzymes (the usual worry with anything you ship to the liver) stayed within normal ranges. No red flags on bilirubin or platelets either.
What November's Presentation Will (and Won't) Tell Us
The upcoming AHA presentation covers Phase 1b results in patients with severe hypertriglyceridemia, a condition where triglyceride levels are dangerously high and existing therapies often fall short. The abstract title confirms as much: "CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 for Severe Hypertriglyceridemia: Results From Phase 1b Trial."
The actual data remain embargoed until presentation day, so we're flying somewhat blind. But the Phase 1b likely tests whether the lipid-lowering seen in earlier cohorts holds up in sicker patients, and whether the safety profile remains squeaky clean at therapeutic doses.
This is the part of the story where things get consequential. Phase 1 told us the technology works in a controlled setting. Phase 1b starts answering whether it works in the patients who need it most.
The Competitive Landscape Is Tiny (For Now)
If you're looking for a crowded field, this isn't it. The number of companies trying to permanently edit genes to lower cardiovascular risk can be counted on one hand.
The closest rival is Verve Therapeutics' VERVE-201, which uses a slightly different technique called base editing to target ANGPTL3 for refractory hypercholesterolemia. Verve is in Phase 1b, putting CTX310 roughly on par in clinical maturity.
The bigger competitive threat actually comes from a completely different technology: RNA interference. Arrowhead Pharmaceuticals' zodasiran silences ANGPTL3 using siRNA and is in Phase 3 development. Eli Lilly's solbinsiran also targets ANGPTL3 using siRNA, with a completed Phase 2 trial. The catch? siRNA treatments need to be repeated periodically, like getting an oil change versus rebuilding the engine. Gene editing's promise is permanence; RNA therapies trade that for a longer track record and simpler regulatory path.
For CRISPR Therapeutics, proving that "one and done" actually means "one and done" over years of follow-up will be the key differentiator.
Why This Matters Beyond One Drug
CRISPR Therapeutics already has a commercial gene-editing product: Casgevy, approved for sickle cell disease and transfusion-dependent beta-thalassemia. But Casgevy is an ex vivo therapy, meaning doctors edit cells outside the body and transplant them back in. It's complex, expensive, and limited to blood disorders.
CTX310 represents something fundamentally different. This is in vivo editing: inject the therapy, let it find its target inside the body, and let biology do the rest. If it works for ANGPTL3, the same lipid nanoparticle platform could theoretically be aimed at dozens of other liver-expressed genes.
The company is already building that broader playbook. CTX321 targets Lp(a), another stubborn cardiovascular risk factor. CTX340 goes after refractory hypertension. CTX611, a long-acting siRNA therapy developed with Sirius Therapeutics, addresses thrombosis. Cardiovascular disease isn't a side project for CRISPR Therapeutics; it's becoming the central pillar of their post-Casgevy identity.
Analysts have noticed. The consensus view is that CRISPR's long-term value increasingly depends on whether these next-generation programs deliver real clinical results, not just on Casgevy sales. The AHA presentation is, in many ways, a referendum on that entire thesis.
The Bottom Line
November 9 is circled on every cardiovascular investor's calendar. If CTX310's Phase 1b data confirm what Phase 1 hinted at (deep, durable, safe lipid lowering from a single dose) it won't just be good news for CRISPR Therapeutics. It'll be a proof point for an entirely new category of medicine: one-time gene editing for common chronic diseases.
We've cured rare blood disorders with CRISPR. The question now is whether we can use the same molecular scissors on conditions that affect hundreds of millions of people. That's the real stakes behind one late-breaking presentation slot in a conference hall in November.
Clinical & Regulatory5 min read
Two Bad Days in Biotech: A Cancer Drug Under Fire and a Weight-Loss Pill That Wasn't Enough
FDA review documents rattled Revolution Medicines investors by hinting its pancreatic cancer drug works better in some patients than others. Meanwhile, Zealand Pharma's obesity drug delivered solid results that would've been impressive five years ago, but in the age of GLP-1 blockbusters, "solid" doesn't cut it.
